- Home
- HSDT vs NRXS Comparison
HSDT vs NRXS Comparison
Compare HSDT & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSDT | NRXS |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.2M | 78.9M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | HSDT | NRXS |
|---|---|---|
| Price | $1.48 | $6.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 287.1K | 159.3K |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | $91.56 | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $0.30 | $2.20 |
| 52 Week High | $25.50 | $9.33 |
Technical Indicators
Market Signals| Indicator | HSDT | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 27.64 | 42.63 |
| Support Level | N/A | $6.51 |
| Resistance Level | $2.39 | $7.85 |
| Average True Range (ATR) | 0.16 | 0.47 |
| MACD | -0.09 | -0.09 |
| Stochastic Oscillator | 4.62 | 14.87 |
Price Performance
Historical ComparisonAbout HSDT Helius Medical Technologies Inc. (DE)
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).